Sierra Oncology is a late stage drug development company focused on developing momelotinib, a potent, selective and orally-bioavailable JAK1, JAK2 & ACVR1 inhibitor, for myelofibrosis. Momelotinib's differentiated therapeutic profile encompasses constitutional symptom improvements, anemia benefits, and spleen control. Sierra has launched the MOMENTUM, a randomized double-blind Phase 3 clinical trial designed to enroll 180 myelofibrosis patients who are symptomatic and anemic, and who have been treated previously with a JAK inhibitor.
Location: Canada, British Columbia, Vancouver
Employees: 51-200
Total raised: $34M
Founded date: 2003
Investors 6
| Date | Name | Website |
| - | RA Capital... | racap.com |
| - | OrbiMed | orbimed.co... |
| - | Adams Stre... | adamsstree... |
| - | Abingworth... | abingworth... |
| - | Vivo Capit... | vivocapita... |
| - | Longitude ... | longitudec... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 10.08.2021 | - | $34M | - |
Mentions in press and media 12
| Date | Title | Description |
| 04.10.2024 | Frazier Life Sciences: Over $630 Million Added To Evergreen Public Fund | Frazier Life Sciences (FLS), a healthcare investment firm focused on innovative therapeutics, announced it has closed on over $630 million in capital commitments to its evergreen Public Fund from new and existing investors in an oversubscri... |
| 13.04.2022 | Will Solana become the base layer of Web3? | This is the web version of Term Sheet, a daily newsletter on the biggest deals and dealmakers. Sign up to get it delivered free to your inbox. Web3 will be the supposed new iteration of the internet. And it will be built on Solana blockchai... |
| 25.01.2022 | Sierra succeeds where Gilead missed; FDA filing now planned for blood cancer drug | A drug abandoned by Gilead Sciences is turning out to have much better prospects under Sierra Oncology. A growing slate of pivotal clinical data support the small molecule’s case as a better treatment choice for a rare blood cancer compared... |
| 09.08.2021 | Sierra Oncology : Provides Update to Momelotinib Development Timeline and Closes on $34 Million in Additional Funding | Sierra Oncology, Inc. (NASDAQ: SRRA), a late-stage biopharmaceutical company on a mission to deliver targeted therapies that treat rare forms of cancer, today updated guidance on the development timeline for its lead product candidate, mome... |
| 09.08.2021 | Sierra Oncology Provides Update to Momelotinib Development Timeline and Closes on $34 Million in Additional Funding | - |
| 07.11.2019 | Sierra Oncology Announces Pricing of $103 Million Public Offering of Convertible Preferred Stock and Warrants | - |
| 18.08.2019 | FDA approves first drug for blood disorder myelofibrosis since 2011 | Prior to Inrebic’s approval, the only drug approved for myelofibrosis was Incyte’s Jakafi (ruxolitinib), which the FDA approved in 2011. Both drugs belong to a class known as JAK inhibitors. Jakafi is intermediate or high-risk myelofibrosis... |
| 15.09.2018 | 40 AND UNDER: The Silicon Valley biotech stars who are backing startups aiming to cure disease, prolong life, and fix the food system | This story is available exclusively to Insider subscribers. Become an Insider and start reading now. Putting millions of dollars into bold new technologies can be a delicate business when lives hang in the balance. But every day some of the... |
| 15.08.2018 | Artios raises $84M for developing cancer drugs targeting DNA repair pathway | Artios plans to use the money to advance development of small-molecule programs that target DNA damage response, or DDR, including a lead program targeting DNA polymerase theta. DDR is the natural process by which the DNA in cells is repair... |
| - | Sierra succeeds where Gilead missed; FDA filing now planned for blood cancer drug | A drug abandoned by Gilead Sciences is turning out to have much better prospects under Sierra Oncology. A growing slate of pivotal clinical data support the small molecule’s case as a better treatment choice for a rare blood cancer compared... |
Show more